Navigation Links
Presentations in Medical Technology

Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting

WAYNE, N.J., May 29 /PRNewswire/ -- Bayer Healthcare Pharmaceuticals Inc. today announced that several studies evaluating the use of Leukine(R) (sargramostim) will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting. "We are excited to see that several studi...

Kensey Nash Announces Presentations on its Cartilage Repair Device at the International Cartilage Repair Society Meeting

EXTON, Pa., May 26 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY ) announced that its cartilage repair device has been highlighted in two podium presentations at the 8th World Congress of the International Cartilage Repair Society (ICRS) Meeting held in Miami, FL on May 23-26, ...

Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting

MALVERN, Pa., May 26 /PRNewswire/ -- Ascenta Therapeutics announced today that eleven presentations or publications on pre-clinical and clinical studies of AT-101, an oral, pan-Bcl-2 inhibitor, in several major tumor types will be made during the 2009 American Society of Clinical Oncology (ASCO) A...

Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annual Meeting

Safety and Efficacy Data from Phase 3 Study will be Highlighted SAN DIEGO, May 7 /PRNewswire-USNewswire/ -- Chronic pain is a significant medical challenge in the United States, and chronic low back pain is the most common cause of disability in developed countries. An estimated 100 million A...

Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases

Clinical results and advantage over linezolid in resistance acquisition by Staph aureus among data to be presented at infectious disease meeting SAN DIEGO, Calif., May 6 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing best-in-class drugs for the treatment of s...

Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

TAMPA, Fla., April 30 /PRNewswire/ -- Sirion Therapeutics, Inc. announced today that eight presentations related to the Company's products, pipeline and research will be presented at the 2009 annual meeting of The Association for Research in Vision and Ophthalmology (ARVO) in Ft. Lauderdale, FL. ...

Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting

Final results from three large PEGINTRON(TM) clinical studies address key questions in the treatment of hepatitis C COPENHAGEN, Denmark, April 27 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today reported that final results of three large PEGINTRON(TM) (peginterferon ...

Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day

Pivotal Trial Expected to Initiate in 2010 for Blinatumomab NEW YORK, April 24 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today held an R&am...

YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY

MISSISSAUGA, ON, March 13 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today reported that its poster entitled, "Binding properties of the ant...

Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences

RICHMOND, Calif., March 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business ...

Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology

WAYNE, N.J., Dec. 5 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that data on Campath(R) (alemtuzumab) and Leukine(R) (sargramostim) will be presented at the 50th Annual Meeting of the American Society of Hematology (ASH) from December 6-9, 2008 in San Francisco, Californi...

GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting

Presentations Will Highlight Research Conducted in GenVec Malaria Vaccine Program GAITHERSBURG, Md., Dec. 5 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC ) announced today that the company will present on GenVec's malaria vaccine program at the American Societ...

Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008

SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular and inflammatory diseases, and cancer, today announced that data relevant to betrixaban, the company's novel ...

VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA

SAN FRANCISCO, Nov. 6 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it will hold a conference call and webcast to discuss results of the VIA...

Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA

TR-701 Phase 1 Clinical Trial Results Disclosed SAN DIEGO, Oct. 20 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing "Best-in-Class" drugs for the treatment of serious bacterial infections, announced today that the results of multiple studies on its lead progra...

Cytopia Scientific Presentations on JAK2 Inhibitor Program

MELBOURNE, Australia, Oct. 16 /PRNewswire/ -- Cytopia Limited (ASX: CYT) will present data on its JAK2 inhibitor program at two important scientific meetings this month. Dr Emmanuelle Fantino, Head of Biology at Cytopia, will present a lecture entitled Targeted JAK2 Inhibitors for Myeloproli...

Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology

Updated Survival Data for Ipilimumab to be Presented PRINCETON, N.J., Sept. 4 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) announced today that nine clinical abstracts for ipilimumab, an investigational anti-CTLA-4 antibody, in melanoma are scheduled to be the subject of ...

Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences

NEW HAVEN, Conn., Aug. 5 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, announced today that company representatives are givi...

Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting

SEATTLE, May 27 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that the following presentations will be made on its product Zevalin(R) (Ibritumomab Tiuxetan) and its development product OPAXIO(TM) (paclitaxel poliglumex, formerly XYOTAX(TM)) at t...

Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City

SOUTH EASTON, Mass., May 21 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO ) ("PBI") today announced that scientists from the New York University (NYU) School of Medicine, the Brooklyn Hospital Center, and the Harvard School of Public Health made presentations highlighting...

Stereotaxis Market Leadership Reinforced in Core Curriculum and Symposium Presentations at Heart Rhythm 2008

ST. LOUIS, May 20 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) today reported on the favorable endorsements of its Niobe(R) Magnetic Navigation System and Odyssey(TM) information management tools received from key opinion leaders in electrophysiology at Heart Rhythm 2008, the Hea...

BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting

- First in human clinical data highlight safety profile of BSI-201 in subjects with advanced solid tumors - BRISBANE, Calif., May 15 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that data su...

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting

KENILWORTH, N.J., May 15 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ), a leader in advancing the science and treatment of chronic hepatitis C virus (HCV) infection, announced today that data from several clinical studies with PEGINTRON(TM) (peginterferon alfa-2b) and REB...

Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents

Randomized TRIAS HR Pilot Study Compares Genous, Boston Scientific's Taxus(R) Other Presentations Focus on Real-World Use of Genous, Stent's Performance in Patients with AMI, Those Who Could Not Tolerate Dual-Antiplatelet Therapy ...

Kosan Announces Data Presentations at ASCO 2008 Annual Meeting

HAYWARD, Calif., May 14 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) today announced that updated data will be presented on tanespimycin, the company's lead Hsp90 inhibitor, from a Phase 2 trial in combination with Herceptin(R) in patients with HER2-positive metast...

Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology

PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) announced today that the following clinical and preclinical abstracts for ipilimumab in melanoma, prostate cancer and other cancers, as well as for anti-PD-1 and anti-CD70 antibody candidates for cancer treatmen...

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting

KENILWORTH, N.J., April 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ), a leader in advancing the science and treatment of chronic hepatitis C virus (HCV) infection, announced today that final results of the IDEAL study as well as from several other clinical studies wit...

Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors

SAN DIEGO and SUNNYVALE, Calif., April 15 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today announced preclinical data from four presentations at the Annual Meeting of the American Association for Cancer Research (AACR) being held this week in San Diego, CA. Results from mul...

SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting

DUBLIN, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that multiple abstracts have been a...

Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART

PRINCETON, N.J., Dec. 11 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) announces that interim results of physician-sponsored studies of clevudine for the treatment of chronic hepatitis B virus (HBV) and both preclinical and clinical results of R7128 for the treatment of chronic h...

TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH

SAN DIEGO, Dec. 6 /PRNewswire/ -- TargeGen, Inc. today announced that the Company's recently submitted IND for TG101348 is now active and the Company plans to initiate a multi-center clinical trial of TG101348, an internally discovered, oral, potent, and highly selective JAK2 inhibitor in Janu...

CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting

BRANFORD, Conn., Nov. 26 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ), a clinical-stage biopharmaceutical company focused on oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today that updated preliminary clinical trial results from the Phase II study ...

Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting

KENILWORTH, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Leading researchers will present 68 data presentations involving Schering-Plough's hepatitis products, including PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy, a current standard of care in the trea...

Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference

DALLAS, Oct. 29 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that two posters describing significant preclinical studies performed by Access collaborators at two prominent institutes in France, were presented last week at the joint symposium...

Threshold to Host Conference Call to Discuss Results From Clinical Presentations at European Cancer Conference (ECCO)

REDWOOD CITY, Calif., Oct. 3 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. (Nasdaq: THLD ), will host a conference call today at 4:30 p.m. ET to discuss the Phase 2 and Phase 3 presentations that were made at the ECCO proceedings last week. Joining the Company on the conference c...

Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)

Detailed Data from the Phase 3 Glufosfamide and Phase 2 Glufosfamide Plus Gemcitabine Clinical Trials to be Presented REDWOOD CITY, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. (Nasdaq: THLD ), today announced two presentations regarding its oncology p...

Oridion Announces Major Medical Research and Congress Presentations

JERUSALEM and NEEDHAM, Massachusetts, June 17 /PRNewswire-FirstCall/ -- Oridion Systems Ltd. - (SWX: ORIDN) Significant findings from numerous medical research projects demonstrating the clinical benefit of end-tidal CO2 (EtCO2) monitoring using Microstream(R) capnography technology, were rece...

IDM Pharma Announces Upcoming Clinical Data Presentations

IRVINE, Calif., Oct. 26 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI ), a biotechnology company focused on the development of innovative cancer therapies, today announced details on clinical data presentations evaluating three of the Company's pipeline compounds to be presented at...

Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology

TAMPA, Fla.--(BUSINESS WIRE)--Mar 7, 2007 - Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI), presented three posters at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology from February 23 - 27, 2007 in San Diego, CA. The posters discussed findings from a survey of 202 ot...

Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL

The 42nd Annual Meeting of the European Association for the Study of the Liver PRINCETON, N.J., April 03, 2007 /PRNewswire/ -- Pharmasset announced today that presentations of preclinical studies of Clevudine for the treatment of hepatitis B (HBV) and PSI-6130, the parent molecule of R7128, for th...
Other Tags
(Date:7/11/2014)... available in German . ... that uses the refraction of X-rays through a specimen ... with this method are often of much higher quality ... team of Prof. Franz Pfeiffer are particularly interested in ... including X-ray phase-contrast imaging. One main goal is ...
(Date:7/11/2014)... at the National Institute of Standards and Technology ... work more effectively, they often prove that necessity ... the case recently for M. Lorna De Leoz ... growing specialization of glycomics. Glycomics is the study ... that are attached to proteins and lipids and ...
(Date:7/11/2014)... 2014, Shenzhen, China Researchers from Salk Institute for ... first time evaluated the safety and reliability of ... developed a new method, TALEN-HDAdV, which could significantly ... cell (hiPSC). This study published online in ... foundation for stem cell-based gene therapy. , The ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2
(Date:7/11/2014)... 11, 2014 According to a new ... Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, Wi-Fi, NFC, ... Automotive & Transportation, Agriculture) & Geography - Global Trends ... Internet of Things market was worth $1029.5 Billion in ... 2020, at an estimated CAGR of 4.08% from 2014 ...
(Date:7/11/2014)... Biostimulants are widely applied in turf and ornamentals. ... also help turf and ornamentals in absorption of water, ... and flowers appear healthy and strong as a result ... the last few years. The most dominating region in ... around 40% share in 2013, and is estimated to ...
(Date:7/11/2014)... July 11, 2014 As reported by ... FiercePharma (Weintraub 7/11/14), a significant number of severe adverse ... abdominal issues and even death from the highly-promoted and ... to the Times report , a regulatory filing ... reported by patients was almost 14% of prescriptions, up ...
(Date:7/11/2014)... and overweight firefighters are not receiving weight management ... new research from The University of Texas Health ... state that health care professionals (HCPs) should advise ... weight. Firefighters have high rates of obesity, and ... deaths in firefighters. This study assessed the association ...
(Date:7/11/2014)... The Corn Farming industry experienced ... the heels of fresh biofuel demand. The Federal Renewable ... larger share of their farmland to cultivating high-value corn ... the mixing of 5.0% renewable content in gasoline across ... States created a key export market for Canadian corn, ...
Breaking Medicine News(10 mins):Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3
Other Contents